Sansure Biotech disclosed its interim report on August 26. In the first half of 2026, it achieved operating revenue of 834 million yuan, down 3.95% year on year. Net profit attributable to shareholders of the listed company was 98.0173 million yuan, down 39.76% year on year. Basic earnings per share were 0.17 yuan. The company plans to distribute a cash dividend of 2.65 yuan, tax included, for every 10 shares. During the reporting period, reagent sales were affected by price declines driven by centralized procurement, medical insurance cost controls, and payment method reforms. The growth hormone products of its subsidiary Zhongshan Haiji were affected by expanded medical insurance coverage and product price cuts. In addition, the value-added tax rate on self-produced testing reagent products in the in vitro diagnostics industry was raised from 3% to 13%, which had a significant impact on profit. Furthermore, the company increased strategic investment in instruments, research and development innovation, and industrial mergers and acquisitions integration. The related increase in investment diluted profit in the short term.
Sansure Biotech IncFirst-half net profit fell 39.76% year on year due to price declines, tax rate increase, and higher investment, with a dividend planned.
